Johnson & Johnson (JNJ) is trading in the green after posting excellent third quarter results. Analysts think that the company is set to gain value in the future amid a rising revenue in emerging markets like China and Brazil. Johnson & Johnson ’s pharmaceutical business is also thriving. The company’s new drug Stelara posted a 73% jump in worldwide sales in the third quarter. Johnson & Johnson ’s Xarelto is in the phase 3 stage while five other drugs are waiting for approval.
The company plans to launch more than 10 blockbuster drugs over the next 5 years. Johnson & Johnson ’s valuation is also attractive. The stock is trading at a PE ratio of 18.9, while the industry average is 25.
Based on the analysts' consensus: both the revenue and the net result would be on record levels. For this year Johnson & Johnson 's revenue will be around 76,27 billion USD. This is according to the average of the analysts' estimates. The expected revenue would be the highest in her history. This is slightly more than 2016's revenue of 71,89 billion USD.
The analysts anticipate for 2017 a record net profit a 19,96 billion USD. According to most of the analysts the company will have a profit per share for this book year of 7,27 USD. So the price/earnings-ratio equals 19,35.
Per share the analysts expect a dividend of 3,33 USD per share. Thus the dividend yield equals 2,37 percent. The average dividend yield of the health care companies equals a moderate 0,20 percent.
ValueSpectrum.com News Wire & Equity Research: +31 084-0032-842
news@valuespectrum.com
Copyright analist.nl B.V.
All rights reserved. Any redistribution, duplication or archiving prohibited. analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.